Every 10-Q that Q32 Bio Inc. (QTTB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QTTB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QTTB filings page.
Q32 Bio Inc. is a clinical stage biotechnology company developing bempikibart, a fully human anti‑IL‑7Rα antibody, for alopecia areata and other autoimmune and inflammatory diseases. It has no approved products and continues to invest heavily in research and development.
For the quarter ended June 30, 2026, the company reported a net loss of $8.9 million, or $0.44 per share, compared with $9.5 million, or $0.78 per share, a year earlier. For the first six months of 2026, the net loss was $16.6 million versus $20.5 million in the prior‑year period.
Cash and cash equivalents were $106.3 million at June 30, 2026, up from $48.3 million at year‑end 2025, driven by a registered direct offering, at‑the‑market sales and a private placement, while venture debt was fully repaid. Subsequent to quarter‑end, a follow‑on public offering added $187.6 million of net proceeds, further strengthening liquidity. Management expects existing cash to fund operations for at least one year, though additional capital will ultimately be required.
Q32 Bio Inc. is a clinical-stage biotech focused on bempikibart for alopecia areata and other autoimmune diseases. For the quarter ended March 31, 2026, it reported a net loss of $7.6 million, improved from $11.0 million a year earlier, as research and development expenses fell to $3.2 million and general and administrative costs to $4.5 million.
Cash and cash equivalents were $50.8 million, with total cash, cash equivalents, restricted cash and restricted cash equivalents of $51.4 million. Management believes this is sufficient to fund operations for at least one year from the financial statement issuance date, though the company expects continued operating losses and will likely need additional capital over time.
During the quarter, Q32 completed a registered direct offering, issuing 1,666,679 shares of common stock and pre-funded warrants for net proceeds of $10.4 million. It also put in place an at-the-market equity program allowing sales of up to $14.2 million of common stock under an effective shelf registration, with no ATM shares sold by March 31, 2026. After quarter-end, the company sold 2,326,952 shares under the ATM for $13.8 million in net proceeds and expanded the ATM capacity by filing a prospectus supplement for up to an additional $75 million.
Q32 Bio (QTTB) reported third‑quarter 2025 results showing sharply lower operating spend and a narrower loss, alongside a reduced cash balance and an equity deficit. Cash and cash equivalents were $49.0 million as of September 30, 2025, down from $78.0 million at year‑end. Total assets were $57.8 million against total liabilities of $76.2 million, resulting in stockholders’ equity (deficit) of $(18.4) million.
Quarterly net loss was $7.4 million versus $17.6 million a year ago as research and development fell to $3.6 million from $14.3 million, with general and administrative at $4.0 million. For the nine months, net loss totaled $27.9 million, and operating cash outflow was $27.4 million. The company expects its cash to fund operations for at least one year from the financial statement issuance date. Management executed a February 2025 restructuring to prioritize bempikibart in AA, discontinued the Phase 2 ADX‑097 renal basket trial, and recorded $0.9 million of severance costs. The company also completed the sale of its 10% OXB (US) LLC interest for $2.5 million and eliminated the related CVR liability by quarter end.